Absci Corporation
$8.15
The Read: ABSI's stock has historically declined on anticipated or actual revenue misses and equity dilution concerns despite positive ABS-201 clinical updates, but rallied sharply when strategic pivots and manageable funding paths alleviated investor fears.
Price
Overlays
Panel
ABSI
Hover to view data
No Data